BCAT-IN-4 Secrets
MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research to evaluate several intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Primary demo targets were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis patie